Wood's $498,000 purchase through a trust vehicle expands his beneficial stake to 338,103 shares as the medical robotics firm navigates losses despite $337.3 million in trailing revenue.

HYDROS revenue surged 32% amid legacy account softness and accelerated replacements.

Price targets for PROCEPT BioRobotics have been reset closer to its revised fair value, with many now clustered in the low to mid US$20s instead of around US$30. Analysts linking these lower targets to slower procedure trends, competition risk and the overhang from recent legal actions have shifted several ratings to Hold, Neutral or Market Perform. As you read on, you will see how this evolving analyst narrative may shape how you track PROCEPT BioRobotics from here. Analyst Price Targets...

Moby summary of PROCEPT BioRobotics Corporation's Q2 2026 earnings call

Despite record system ASPs and robust new account performance, the company lowers full-year procedure guidance as legacy AquaBeam sites underperform.

PROCEPT BioRobotics (NASDAQ:PRCT) reported second-quarter revenue growth of 19% year over year while lowering its full-year U.S. procedure outlook, citing softer activity at legacy AquaBeam accounts. Management said newer HYDROS Robotic System accounts continued to show stronger utilization, support

PROCEPT BIOROBO (PRCT) delivered earnings and revenue surprises of -2.17% and +2.16%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

In the past week, multiple securities law firms, including Robbins Geller Rudman & Dowd LLP and Rosen Law Firm, announced class action lawsuits against PROCEPT BioRobotics, alleging undisclosed discounting practices that inflated reported U.S. handpiece sales and conflicted with prior guidance between February 2024 and February 2026. The lawsuits focus on claims that PROCEPT’s bulk-order discount program pulled sales forward, left more than 10,000 excess handpiece units in the field, and...

The acquisition transforms Processa’s pipeline with the addition of clinical-stage BTK inhibitor VT-7208, while a concurrent $200 million private placement is expected to fund development into 2029. Key Investor TakeawaysProcessa Pharmaceuticals (NASDAQ:PRCT) acquired Vidya Therapeutics, adding clinical-stage BTK inhibitor VT-7208 to its pipeline.

PROCEPT BioRobotics (PRCT) is back in focus after a class action lawsuit filed in federal court alleged the company used undisclosed discount programs that inflated sales metrics and contributed to excess inventory. See our latest analysis for PROCEPT BioRobotics. At a latest share price of $17.69, PROCEPT BioRobotics has seen a 1-day share price return of 5.99%, although the 30-day share price return is down 21.59% and the year-to-date share price return is down 42.49%. The 1-year total...